Chemfab Alkalis Ltd Valuation Shifts Signal Heightened Price Risk

Valuation Metrics Reveal Elevated Risk

Chemfab Alkalis’ current P/E ratio of -206.02 is a stark indicator of the company’s loss-making status, reflecting negative earnings over the trailing twelve months. This contrasts sharply with peer companies in the commodity chemicals space, many of which maintain positive P/E ratios despite sector volatility. For instance, Titan Biotech and Sanstar Chemicals, both rated as very expensive, report P/E ratios of 70.18 and 92.43 respectively, while Gulshan Polyols, deemed very attractive, trades at a more reasonable 28.09. The negative P/E for Chemfab Alkalis thus signals a fundamental earnings challenge that investors must weigh carefully.

Meanwhile, the P/BV ratio of 1.74, although not excessively high in absolute terms, has contributed to the company’s reclassification to a very expensive valuation grade. This suggests that the market price is nearly twice the book value of the company’s net assets, a premium that may be difficult to justify given the firm’s weak return on equity (ROE) of just 0.82% and return on capital employed (ROCE) of 1.80%. These returns are significantly below industry averages, indicating limited efficiency in generating profits from shareholder funds and capital investments.

The enterprise value to EBITDA (EV/EBITDA) multiple stands at 24.03, which is elevated compared to several peers. For example, Gulshan Polyols trades at an EV/EBITDA of 12.19, and TGV Sraac at 4.24, both considered very attractive valuations. Chemfab Alkalis’ high EV/EBITDA multiple further underscores the market’s premium pricing despite the company’s operational challenges.

Stock Price Performance and Market Context

On the price front, Chemfab Alkalis closed at ₹447.10 on 12 May 2026, down 4.88% from the previous close of ₹470.05. The stock’s 52-week range spans from ₹270.00 to ₹900.00, indicating significant volatility over the past year. Despite this, the stock has outperformed the Sensex over several time horizons, with a 1-week return of 8.39% versus the Sensex’s -1.62%, and a 1-month return of 14.46% compared to the Sensex’s -1.98%. However, longer-term performance paints a more cautious picture: the stock has declined 44.63% over the past year, while the Sensex fell only 4.33%. Over three and five years, Chemfab Alkalis has delivered robust cumulative returns of 52.57% and 194.14% respectively, outperforming the Sensex’s 22.79% and 54.62% gains, but these gains have come with heightened risk and volatility.

Comparative Valuation and Peer Analysis

When benchmarked against its peers, Chemfab Alkalis’ valuation metrics stand out for their extremity. The company’s EV to EBIT ratio is an eye-watering 769.78, far exceeding typical industry levels and signalling either depressed earnings or an inflated enterprise value. This contrasts with peers such as Stallion India and Platinum Industries, which, while also expensive, report EV to EBIT multiples of 35.34 and 21.35 respectively. The EV to capital employed ratio of 1.58 and EV to sales of 2.34 further highlight the premium valuation placed on Chemfab Alkalis despite its operational underperformance.

Dividend yield remains negligible at 0.26%, reflecting limited cash returns to shareholders. This is consistent with the company’s low profitability and reinvestment needs. Investors seeking income or stable returns may find this yield insufficient, especially given the valuation premium.

Mojo Score and Rating Update

MarketsMOJO’s proprietary scoring system assigns Chemfab Alkalis a Mojo Score of 24.0, categorising it as a Strong Sell. This represents a downgrade from its previous Sell rating as of 7 July 2025, reflecting deteriorating fundamentals and valuation concerns. The micro-cap status of the company adds an additional layer of risk, given typically lower liquidity and higher volatility associated with smaller market capitalisations.

Investment Implications and Outlook

Investors considering Chemfab Alkalis must weigh the company’s stretched valuation against its weak profitability and operational metrics. The negative P/E ratio and elevated EV multiples suggest that the market is pricing in expectations that may be difficult to realise without a significant turnaround in earnings. The company’s low ROE and ROCE further underscore challenges in generating shareholder value.

While the stock has demonstrated strong cumulative returns over the medium term, recent price declines and the strong sell rating indicate caution. The micro-cap nature of Chemfab Alkalis also implies higher risk, including potential liquidity constraints and greater sensitivity to market sentiment.

Comparatively, several peers in the commodity chemicals sector offer more attractive valuations and stronger fundamentals, presenting alternative investment opportunities for risk-conscious investors. The current valuation premium on Chemfab Alkalis may not be justified given its financial profile, suggesting that investors should consider rebalancing portfolios accordingly.

Conclusion

Chemfab Alkalis Ltd’s shift from expensive to very expensive valuation status, driven by a deeply negative P/E ratio and elevated price-to-book and EV multiples, signals heightened price risk amid ongoing operational challenges. The company’s weak returns on capital and micro-cap classification compound these concerns, leading to a strong sell recommendation from MarketsMOJO. Investors are advised to approach the stock with caution and consider peer alternatives offering superior valuation and financial health.

Get Started for only Rs. 16,999 - Get MojoOne for 2 Years + 1 Year Absolutely FREE! (72% Off) Start Today